# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ray Charles (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML009-SYN-TD
- Date: 1996-03-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gloria Fenwick, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for establishing primary care: accessible care for a blind adult, recovery-oriented review, and depression and safety screening. **S**

## Objective

Hemoglobin: 14.2 g/dL; Sodium: 139 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 0.98 mg/dL; eGFR: 84 mL/min/1.73 m²; Glucose: 94 mg/dL; Calcium: 9.4 mg/dL; Total cholesterol: 186 mg/dL; HDL cholesterol: 54 mg/dL; LDL cholesterol: 110 mg/dL; Triglycerides: 110 mg/dL; HbA1c: 5.5%; PHQ-9: 2; AUDIT-C: 2; DAST-10: 0. All results are synthetic.

BP 128/78 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 80 kg; BMI 25.2 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Blindness of both eyes since childhood, no light perception; cause never diagnosed; Opioid use disorder (heroin), in sustained remission for more than thirty years, without medication treatment. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils **S**

## Plan

- Disability-competent care at every visit: introductions and spoken orientation, describing each step of the examination, offering an arm for guiding, and all documents in an accessible electronic format. Guideline: Vision Rehabilitation Preferred Practice Pattern (2023) **S**
- Ophthalmology consultation to examine the blind eyes for comfort and complications and to advise on pressure checks and surveillance. Guideline: Primary Open-Angle Glaucoma Preferred Practice Pattern (2025); CMID: Clinical Monitoring Intelligence Database, glaucoma and depression, bipolar, and mood disorders monographs (2026) **S**
- Recovery-oriented care: ask about cravings, triggers, and any return to use at each visit in a non-judgmental way; naloxone at home and when traveling; recovery supports he can reach; and a written plan for any future pain. Guideline: VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020) **S**
- Depression screening with the PHQ-9 at intake and at six months, PHQ-2 at the wellness visit, and a safety review with the 988 Suicide & Crisis Lifeline at each visit. Guideline: Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, glaucoma and depression, bipolar, and mood disorders monographs (2026) **S**
- Medicine labeling: audio labels from the pharmacy, a braille label on the naloxone, and the same pharmacy for every prescription. Guideline: Vision Rehabilitation Preferred Practice Pattern (2023) **S**
- Fall prevention: CDC STEADI screen at each visit, keeping the home layout unchanged, and a sighted guide in unfamiliar places. Guideline: Vision Rehabilitation Preferred Practice Pattern (2023) **S**
